Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.24.2.u1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 01, 2021
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Disaggregation of Revenue [Line Items]          
Total revenue   $ 0 $ 643 $ 0 $ 1,117
Discontinued Operations, Disposed of by Sale          
Disaggregation of Revenue [Line Items]          
Other long-term debt   1,000   1,000  
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio          
Disaggregation of Revenue [Line Items]          
Proceeds from divestiture of businesses       1,000  
Product revenue, net          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 0 $ 643 $ 0 $ 1,117
Millipred | Teva          
Disaggregation of Revenue [Line Items]          
Percent of net profit for installment payments 50.00%        
Installment payment $ 500